Online ISSN: 1949-2553

Oncotarget Sponsors Sergei Kurenov in the 2018 Ride for Roswell

September 24, 2018
Established in 2010, Oncotarget is a bio-medical journal focused on the publication of high-impact research in the fields of traditional cancer research and beyond. The 2017 Scopus journal ranking is 1.942 and Oncotarget has held a Q1 status for 7 years straight.  Oncotarget ranks #1 on total documents (2016 & 2017) amongst all journals in Oncology according to Schimago Journal Ranks and remains among the top-ranked medical journals in the category of cancer-related research, based on cites per document in Scopus. In addition to its commitment to publishing high quality research in these fields, Oncotarget also supports major research through… continue reading »

Do a ketogenic diet and fat supplements make chemo more effective for children?

February 12, 2018
A ketogenic diet (aka “keto”) is a low-carb, high-fat diet designed to put your body into a metabolic state called ketosis. Many popular diets are based on this premise. In a recent study described in Oncotarget, Volume 8, Issue 39, researchers wanted to find out if a keto diet supplemented with over-the-counter partially man-made fats (medium-chain triglycerides) enhanced the anti-tumor effects of chemotherapy on a cancer most commonly found in children (neuroblastoma). Neuroblastoma (NB) is the second most common solid cancer in children occurring outside the skull, accounting for ~15% of pediatric cancer deaths. Despite treatment advances, the outcome for… continue reading »



Stopping the spread of cancer

February 12, 2018
Ewing sarcoma is a rare cancer with a high cure rate—if it can be treated before it spreads. New research has identified a treatment approach that can help prevent the cancer from spreading. Ewing sarcoma (ES) is a type of cancer that forms in bones and the tissue around bones, and was first identified by the researcher James Ewing in 1920. It mostly affects children and young adults between the ages of 10 and 20. Researchers at Johns Hopkins University, the University Medical Center Düsseldorf, and the University of Washington recently published a paper in Oncotarget examining the role of… continue reading »

Desperate to stop skin cancer from spreading to brain cancer, researchers look at the action of the gene ANGPTL4

February 12, 2018
When cancer cells break away from where they first formed and travel through the blood or lymph system to form new tumors (called metastasis), they become what is currently the major cause leading to death from cancer. Treating metastasis is complex since in many cases, this spreading of the cancer cells has already occurred by the time the disease is diagnosed. The growth and progression of cancer cells spreading to other parts of the body is dependent on the traits of the tumor, and how the cancer cells interact with the cells and cell secretions from the part of the… continue reading »

Role of protein in KRAS mutation in pancreatic cancer explored

February 12, 2018
Pancreatic cancer is a devastating disease that is often associated with mutation of a gene called KRAS. Improvement of pancreatic cancer therapy requires sensitive early detection techniques and a better understanding of the biology involved in the formation or presence new, abnormal pancreatic tissue (pancreatic neoplasia). As described in Oncotarget, Volume 8, Issue 54, researchers studied the role of the antioxidant protein called Prdx1 in pancreatic abnormal tissue growth and cancer by determining how it regulates the gene KRAS. In general, when the KRAS gene mutates, it can cause normal cells to become cancerous. Likewise this KRAS mutation can activate… continue reading »